Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Update

Capstone Therapeutics Corp. (NASDAQ:CAPS) saw a significant growth in short interest in May. As of May 29th, there was short interest totaling 321,408 shares, a growth of 210.7% from the May 14th total of 103,447 shares. Based on an average daily volume of 14,882,138 shares, the short-interest ratio is presently 0.0 days. Approximately 4.2% of the shares of the stock are sold short.

Capstone Therapeutics Stock Performance

NASDAQ CAPS opened at $0.30 on Friday. Capstone Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $2.07. The stock has a market cap of $3.81 million, a price-to-earnings ratio of -0.09 and a beta of -1.54. The business has a fifty day moving average of $0.40 and a 200-day moving average of $0.59. The company has a quick ratio of 0.29, a current ratio of 0.95 and a debt-to-equity ratio of 0.79.

Capstone Therapeutics (NASDAQ:CAPS) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Capstone Therapeutics had a negative return on equity of 114.15% and a negative net margin of 41.26%.The company had revenue of $12.64 million during the quarter, compared to analyst estimates of $10.80 million.

Hedge Funds Weigh In On Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC acquired a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 2.55% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.